scispace - formally typeset
A

Adam Kesingland

Researcher at Novartis

Publications -  8
Citations -  1260

Adam Kesingland is an academic researcher from Novartis. The author has contributed to research in topics: Neuropathic pain & Hyperalgesia. The author has an hindex of 8, co-authored 8 publications receiving 1234 citations.

Papers
More filters
Journal ArticleDOI

The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain

TL;DR: The data show that cannabinoids are highly potent and efficacious antihyperalgesic agents in a model of neuropathic pain and mediated via an action in both the CNS and in the periphery.
Journal ArticleDOI

The effects of GABAB agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat

TL;DR: Examination of the effects of a novel GABAB agonist in models of chronic neuropathic and inflammatory pain in the rat and its inhibitory action on spinal transmission in vitro indicates that CGP35024 and L‐baclofen modulate nociceptive transmission in the spinal cord to inhibit neuropathic hyperalgesia, and that C GP35024 has a therapeutic window for antihyperalgesIA over spasmolysis.
Journal ArticleDOI

The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. (Novartic Institute for Medical Sciences, London, United Kingdom) Pain. 2001;92:91–100.

TL;DR: Cannabinoids are highly potent and efficacious antihyperalgesic agents in a model of neuropathic pain and are likely to be mediated via an action in the CNS and in the periphery.
Journal ArticleDOI

Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.

TL;DR: It is concluded that zoledronic acid, in addition to, or independent from, its anti‐metastatic and bone preserving therapeutic effects, is an anti‐nociceptive agent in a rat model of metastatic cancer pain.